Moderna stock drops more than 7% after positive melanoma vaccine results and FDA flu shot approval

Traders Union
All News
Stocks
Moderna slides 7.32% today on selloff

Highlights

Moderna reported positive Phase 3 results for its individualized mRNA-based melanoma vaccine developed with Merck & Co.
The FDA approved Moderna's mRNA-based flu vaccine for adults over 50, aiming for market release in the 2026 to 2027 season.
Shares of Moderna are trading above key moving averages with bullish momentum, but intraday losses and volatility signal strong selling pressure around $134.05 support and $159.2 resistance, with the five-day expected range at $107.6 to $161.4.

Positive trial data and institutional buying as selling pressure persists

Moderna released positive Phase 3 trial results for its individualized mRNA-based cancer vaccine for melanoma, developed with Merck & Co. The U.S. FDA approved Moderna's new mRNA-based flu vaccine for adults over 50, which is planned for market release in the 2026–2027 flu season. Bank of New York Mellon Corp acquired more than 1.7 million shares, valued at about $119 million, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes the sharp 7.32% drop in Moderna’s price contradicts its bullish technical setup. He sees strong intraday volatility and a deep gap lower as signs institutional sellers remain in control despite positive clinical and regulatory news. Kharitonov points out that even with the stock above key moving averages, overbought signals from RSI, CCI, and BBP suggest the risk of a steep correction. He believes large fund inflows, like Bank of New York Mellon's share acquisition, are insufficient to offset prevailing market distrust. "Current upside appears fragile — I remain cautious until price proves support at $134.05 will hold convincingly."

Viktoras Karapetjanc, expert at Traders Union, emphasizes that Moderna’s bullish structure remains intact. He highlights the positive momentum from both FDA approvals and successful Phase 3 results, which reinforce long-term upside potential. Karapetjanc sees institutional demand, such as significant purchases by Bank of New York Mellon, as validating support for continued growth. He is confident that, barring a break below $134.05, the stock offers strong setups for further gains. "The market’s reaction is temporary — I expect consolidation with a clear pathway to higher levels soon."

Sholanke Dele, market strategist, views the sharp decline as a warning sign for sentiment. He believes the market is reacting to profit-taking and possible skepticism about the longevity of Moderna’s positive news. Dele notes that broader selling pressure has overwhelmed strong fundamental headlines. "The rebound will need clear risk-off signals to reverse this loss — right now, caution is warranted."

Bullish momentum and overbought signals amid elevated volatility

The stock is trading above its 20-day, 50-day, and 200-day moving averages ($72.57, $67.6, and $48.73), maintaining a bullish technical profile across all trends. Immediate support is at $134.05, while resistance is at $159.2. The Ichimoku Kijun ($114.66) confirms the underlying trend. Momentum signals remain strong with both MACD and ADX indicating bullish bias. The RSI is high at 71.6, showing a buy signal but suggesting overbought conditions. CCI and BBP are also strongly overbought, reflecting dominant intraday buyers. The Awesome Oscillator confirms continued bullish momentum. Despite this, today's price action showed a sharp $10.63 (7.32%) drop following an $11.08 downside gap, with the stock near session lows and intraday volatility at 18.76%. This points to significant selling pressure after the open, diverging from the otherwise bullish backdrop.

Earlier, analysts noted that Moderna’s breakthrough in personalized melanoma therapy marked a pivotal shift in the company’s strategy beyond infectious diseases, but emphasized the need for further clinical and commercial clarity. The current technical backdrop, despite a sharp intraday drop, highlights the importance of monitoring whether sustained volatility alters the prevailing bullish structure or triggers a more decisive test of immediate support at $134.05.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.